@aorchid

KPC presence in Pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy.

, , , and . Antimicrob Agents Chemother, 57 (2): 1086--1088 (February 2013)
DOI: 10.1128/AAC.01748-12

Abstract

While reports of Klebsiella pneumoniae carbapenemase (KPC) production among Pseudomonas aeruginosa strains have emerged from a number of countries worldwide, outcome data are lacking. This is the first report evaluating how KPC production in P. aeruginosa impacts the efficacy of carbapenems by using the murine thigh infection model. Our findings suggest that the impact of KPC-2 in vivo is less pronounced than would be anticipated based on the in vitro potency.

Description

addition of KPC to pseudomonas did not really add much in organisms resistant to doripenem already by other mechanisms.

Links and resources

Tags